Navigation Links
Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Date:10/6/2009

AURORA, Ontario, Oct. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").

Helix requested the pre-IND meetings in order to confirm its plans for future investigational new drug ("IND") filings with the FDA. The meeting on Topical Interferon Alpha-2b was designed to confirm the data requirements needed, beyond the completed Phase II cervical dysplasia study to proceed to Phase II/III clinical testing in the U.S. for this indication. The pre-IND meeting on L-DOS47 was designed to receive guidance from the FDA on requirements that must be met by Helix before requesting approval to begin a Phase I study in the U.S.

"We are very pleased with the outcomes of both pre-IND meetings with the FDA," said John Docherty, president and chief operating officer of Helix BioPharma. "Our discussions confirmed our expectations of what is necessary to proceed with both clinical programs and we now have a clearly identified path to progress to those clinical investigations."

Topical Interferon Alpha-2b - Cervical Dysplasia Indication

The pre-IND meeting with the FDA was held to confirm the specific regulatory requirements for commencing U.S. clinical testing of its Topical Interferon Alpha-2b in patients with cervical dysplasia. Based on this meeting, a U.S. Phase II/III, randomized, vehicle-controlled clinical trial will be acceptable as the next clinical trial in Helix's Topical Interferon alpha-2b clinical development program.

As expected, Helix must first demonstrate that there is no significant systemic interferon alpha-2b exposure in the open-label Phase II pharmacokinetic study before filing a U.S. Phase II/III IND. This study is currently underway i
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
5. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, ... and technologies must be able to protect ... (IP). (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ... nature of the Medical Device Industry, it ... industry sectors of cases involving IP infringement. ...
(Date:1/15/2014)... , Jan. 15, 2014 The ... as a Medical Fitness Center by the Medical ... health and fitness centers to achieve their full ... the only certified fitness center in the western ... "The certification means the Cadence Fitness & ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ... aspects in today,s growth in the pharmaceutical ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
(Date:4/16/2014)... 16, 2014 According to a new study, endoscopists, ... with one to two small polyps are consistent with ... may be an appropriate target for quality indicators. This ... adherence to guidelines for timing of repeat colonoscopy after ... colonoscopy in average-risk patients. The study appears in the ...
(Date:4/15/2014)... Cases of diabetes and pre-diabetes in the United States ... the Johns Hopkins Bloomberg School of Public Health, with ... also found that the burden of the disease has ... diabetes in blacks, Hispanics and the elderly. , According ... issue of the Annals of Internal Medicine , ...
(Date:4/15/2014)... Scientists have solved a decades-old medical mystery and ... to fight invasive fungal infections, which kill about 1.5 million ... mechanism of action of amphotericin, an antifungal drug that has ... though it is nearly as toxic to human cells as ... report of the new findings appears in Nature ...
(Date:4/15/2014)... San Diego School of Medicine have identified a mechanism ... get liver disease and why the virus is able ... , The hard-to-kill pathogen, which infects an estimated 200 ... the mitochondria dismantling the cell,s innate ability ... mitochondrial dynamics. , The study, published in today,s issue ...
(Date:4/14/2014)... in South Africa may provide insight on how to ... other areas of the world, which may have limited ... to successful interventions. , A report on the ... that due to the HIV/AIDS pandemic, which has left ... at an increased risk for mental health problems. ...
Breaking Medicine News(10 mins):Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3
... 19 As they rush to save lives in the ... address myths about disaster relief among the American public. Edward ... five myths around disaster relief. , 1. Collecting blankets, shoes ... cost of shipping these items from around the country – let ...
... PORTLAND, Ore. , Jan. 18 To support ... Foundation donated $50,000 to Medical Teams International, a humanitarian ... provide medical assistance to areas throughout the world. The organization has ... , "It is difficult to comprehend the loss of life in ...
... Jan. 18 Tyco International (NYSE: TYC ) ... from continuing operations before special items for the first quarter of fiscal ... or $0.61 to $0.63 per share on a GAAP basis. This ... continuing operations before special items of $0.48 to $0.50 per ...
... from a cost model suggest that expenses for systemic ... rate than inflation, and newer biologically derived treatments are ... report in the January issue of Archives of ... is a chronic autoimmune disease that affects an estimated ...
... urge more doctors to ask simple question of male ... dysfunction is a strong warning sign that a man ... and other cardiovascular problems, a long-running study indicates. , ... Study] risk factors, men with erectile function still had ...
... suggest , MONDAY, Jan. 18 (HealthDay News) -- Appendicitis ... organ isn,t removed quickly, U.S. researchers say in a ... also theorize that viral infections can cause appendicitis. , ... is fast becoming history, thanks to new single-incision surgery ...
Cached Medicine News:Health News:Myths of Disaster Relief 2Health News:Myths of Disaster Relief 3Health News:Regence Foundation Donates $50,000 to Aid Haiti Relief Efforts 2Health News:Tyco International Provides Update on First Quarter 2010 Performance 2Health News:Tyco International Provides Update on First Quarter 2010 Performance 3Health News:Tyco International Provides Update on First Quarter 2010 Performance 4Health News:Tyco International Provides Update on First Quarter 2010 Performance 5Health News:Costs of psoriasis treatments outpace inflation 2Health News:Erectile Dysfunction Predicts Heart Disease 2Health News:Study Questions Need for Emergency Appendectomies 2
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... The BD Macro-Vue RPR (Rapid Plasma ... Tear-drop Tests are nontreponemal testing procedures ... described in A Manual of Tests ... this manual are the most widely ...
Agglutination test on slide for qualitative and quantitative determination of Syphilis in serum or plasma....
... quality assurance reagent in assays detecting IgG and ... TOXO IgM), IgG and IgM antibodies to rubella ... IgM antibodies to cytomegalovirus (CMV IgG and IgM), ... virus types 1 and 2 (HSV-1 IgG, HSV-1 ...
Medicine Products: